Vaccines and CMV Reactivation

The COVID-19 mRNA vaccines are inducing a short-term temporary immunosuppression that allows cytomegalovirus (CMV) to reactivate in some people. This reactivation of cytomegalovirus can cause myocarditis and Guillain-Barré syndrome, and a host of other disorders. Cytomegalovirus is highly ubiquitous in nature and common in people of all ages, and is part of a family of herpesviruses that cause chickenpox and mononucleosis in adolescents. After infection, CMV remains dormant in the body of most humans for life, but can reactivate during immune suppression. Reduced susceptibility to CMV in men over the age of 45 may be the reason why rare cases of myocarditis are occurring in young people who have received the mRNA vaccine. Susceptibility to CMV increases between the ages of 16 and 45. Treatments, medications, and even vaccines can temporarily suppress the immune system and cause CMV reactivation. This should be considered as a possible cause of cases of myocarditis and Guillain-Barré in those who have received the mRNA COVID-19 vaccine.This book lays out the Nuremberg code and briefly explores the circumstances surrounding the vaccine roll-out, before explaining a new theory of health that may provide an answer to the complex pathology of vaccine injury and other chronic diseases.